Addressing Significant Unmet Medical Needs
Developing next-generation therapeutics for diseases representing significant unmet medical needs and a burden to society, patients and their families.
Article + Video: Reviva Pharma CEO On The Trouble With Today’s Schizophrenia Drugs – And How The Company Is Fixing That
Discovering and Developing New Therapies
We are a clinical-stage pharmaceutical company focused on discovering and developing novel therapies for central nervous system, respiratory, and metabolic diseases of huge unmet need. We are committed to developing better, safer, and more effective treatments that can have a real impact on the lives of our patients.
Better Patient Outcomes
Better Safety Profiles
Using chemical genomics driven technology, we are leveraging scientific innovations to discover and develop new medicines with better therapeutic options for patients in need.
Delivering Safe and Efficacious Treatment Options
Our lead drug candidate, brilaroxazine (RP5063), is in clinical development for multiple unmet neuropsychiatric indications including schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychotic symptoms in Alzheimer’s disease, Parkinson’s disease psychosis, and attention deficit hyperactivity disorder (ADHD).
Learn more about our completed and ongoing clinical trials.
Latest News
Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights
- Pre-NDA meeting with FDA to discuss brilaroxazine's path to approval for schizophrenia planned in Q4 2025 - - Potential NDA submission for schizophrenia indication targeted for Q2 2026 - - European patent granted covering use of brilaroxazine for the treatment of...
Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025
CUPERTINO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous...
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis
- Patent covers brilaroxazine use for treating Pulmonary Fibrosis -Similar patents have also been granted in key markets around the world including the United States, China, and Japan -Brilaroxazine has a novel mechanism of action for treating the underlying...
Corporate Presentation
